In this episode, Beyond Biotech explores the challenges and innovations involved in scaling up cell therapy manufacturing. Fabian Gerlinghaus of Cellares shares insights into how smart automation and integrated platforms are transforming this emerging field.

Key Points:

Smart manufacturing is the key to democratizing access to cutting-edge cell therapies. Cellares' approach shows that automation can overcome the limits of traditional biomanufacturing while keeping patients at the centre of innovation.

• The Cell Therapy Bottleneck: Despite breakthroughs in personalized medicine, the manufacturing of cell therapies remains complex, manual, and costly—limiting patient access and slowing global adoption.
• The Cellares Solution: Cellares' Cell Shuttle platform automates 90% of the cell therapy manufacturing process, reducing labor costs, increasing batch consistency, and dramatically speeding up production.
• Smart Manufacturing with Closed Systems: Gerlinghaus emphasizes the importance of a closed, automated system that minimizes contamination risk while enabling parallel production of up to 16 patient therapies at once.
• Scaling Without Compromise: By combining software, robotics, and data tracking, Cellares is building scalable infrastructure that ensures quality control, lowers costs, and supports global distribution.
• A Patient-Centered Future: The goal is to make life-saving cell therapies more widely available, bringing treatments to patients around the world—especially those with rare or hard-to-treat cancers.